THROMBATE III Rx
Generic Name and Formulations:
Antithrombin III (human) 500 IU, 1000 IU; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Grifols Biologicals, Inc.
Indications for THROMBATE III:
Treatment of patients with hereditary antithrombin III deficiency (AT-III) in surgical or obstetrical procedures and thromboembolism.
Give by IV infusion over 10–20 minutes. Individualized. Dose (units required)= [desired (% of normal) – baseline (% of normal) AT-III level] X weight (kg)/1.4. Loading dose: increase AT-III to 120% of normal. Subsequent dose should be based on AT-III levels obtained 20 minutes post-infusion, every 12hrs, and before the next dose. Maintain AT-III levels at 80–120% of normal for 2–8 days.
Surgery. Hemorrhage. Acute thrombosis. Monitor AT-III levels during treatment. Contains human plasma; monitor for possible infection transmission. Pregnancy (Cat.B).
Potentiates anticoagulant effect of heparin; reduce heparin dose.
Thrombin inhibitor (α2-glycoprotein).
Dizziness, chest tightness, nausea, taste disturbances, chills, cramps, shortness of breath, chest pain, light-headedness, bowel fullness, hives, fever, hematoma formation.
Report all infections suspected to be transmitted by Thrombate III to (800) 520-2807.
Single-use vial—1 (w. diluent, needles)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders